Sarepta Therapeutics SRPT

HealthcareMarket cap $10B1 connection

Sarepta develops gene therapies for Duchenne muscular dystrophy - the most common fatal genetic disease in children. Its Elevidys exon-skipping treatment gave hope to thousands of families. Despite regulatory hurdles, Sarepta is the leader in a disease that otherwise has no cure.

Explore Sarepta Therapeutics on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

CRISPR TherapeuticsHealthcare · $4BCompeting DMD gene therapy approaches

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Sarepta Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=SRPT" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Sarepta Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.